A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Recruiting now · Phase 2
Conditions studied: Meningioma
In brief
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Key facts
- Study ID
- NCT07428616
- Run by
- Exelixis
- People needed
- 100
- Starts
- 2026-05-21
- Expected to finish
- 2029-09-30
- Last updated by the study team
- 2026-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama — Birmingham, Alabama, United States (enrolling)
- Mayo Clinic_Arizona — Phoenix, Arizona, United States (enrolling)
- Mayo Clinic_Jacksonville — Jacksonville, Florida, United States (enrolling)
- Baptist Health Miami Cancer Institute — Miami, Florida, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
- Mayo Clinic_Rochester — Rochester, New York, United States (enrolling)
- Duke University — Durham, North Carolina, United States (enrolling)
- UT MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- UT Health San Antonio Mays Cancer Center — San Antonio, Texas, United States (enrolling)
- Inova Center for Personalized Health — Fairfax, Virginia, United States (enrolling)
- UW Carbone Cancer Center — Madison, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.